NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Quit Smoking: Psilocybin Found To Be 6 Times More Effective Than Nicotine Patches
A new clinical trial has found that psilocybin-assisted therapy may be better at helping people stop smoking than standard nicotine replacement treatment. The post Quit Smoking: Psilocybin Found To Be 6 Times More Eff...
Beyond FDA Approval: Psychedelics as Catalysts For Creativity and Innovation
While psychedelics have a history of sparking creativity, the first modern study to investigate the potential of psilocybin to enhance the brain’s ability to unlock creativity and problem solving is underway at the Un...
FDA Grants Breakthrough Therapy Designation to The Psychedelic Luvesilocin for Postpartum Depression
The U.S. The post FDA Grants Breakthrough Therapy Designation to The Psychedelic Luvesilocin for Postpartum Depression appeared first on Psychedelic Health.
Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day
Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of drinking a coffee, with benefits that come and go by day’s end. The post Authors of Largest Microdo...
Personality in Ayahuasca and Cannabis Users
Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users Authors:José Carlos Bouso, Oscar Andión, Sabela Fondevila Estévez, Débora González, Miguel Ángel Alcázar-Córcoles, Maja Koh...
Psychedelics Clinical Trial Update: Positive Results from Psilocybin and DMT on the Road for FDA Approval
Clinical updates from Compass Pathways and Helus Pharma from last week marked a significant step forward in the psychedelics development landscape, with new data emerging from late stage and mid stage programs targeti...
Varying Approaches to Psychedelic Policy Reform in Washington State
Lawmakers in Washington state have been debating two distinct and often conflicting visions for the regulation of psychedelics that reflects national tensions about the future of psychedelic therapies. The post Varyin...
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybi...
Legislation, Industry, and the Future of Psilocybin for PTSD
The FDA acceptance of Compass Pathway’s Investigational New Drug Application for their COMP360 compound as a possible therapy for PTSD introduces a new area of possible therapies using psilocybin. The post Legislati...
MAPS and Columbia University Partner on First-of-its-Kind Study of MDMA-Assisted Couples Therapy
February 2, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announces a formal research partnership with Columbia University to study how practitioners are facilitating MDMA-assisted couples th...
MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study
On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review. This amendment was...
New Theories and Findings From The Frontier of Ibogaine Research
After publishing a new study investigating synthetic analogs for iboga molecules, scientist and co-founder of Gilgamesh Pharmaceuticals, Dalibor Sames, decided to take the compound he has described as an intelligent ...
A Call for Women’s Representation in Psychedelic Research
Based on a scoping review of psychedelic research for substance use disorders, this chronicle explores the persistent underrepresentation of women in clinical studies. The author weaves scientific findings with clinic...
What to Watch Out For in the Psychedelic Sector in 2026
Ismail Lourido Ali, JD, Co-Executive Director of The Multidisciplinary Association for Psychedelic Studies (MAPS), offers thoughts on what to watch out for in the psychedelic sector in 2026. The post What to Watch Ou...
Partners Announced for Texas Ibogaine Research Consortium Funding
The Texas Health and Human Services Commission (HHSC) has announced $50 million in awards to a collective of public universities across the state to establish the Texas Ibogaine Research Consortium. The post Partners ...